Moreover, the anti-tumor efficacy of CD40 agonists in mouse models was greatly improved by engineering Fc variants with enhanced binding to FcγRIIb, including the S267E variant that confers 30-fold increased binding affinity to FcγRIIb [14, 26, 27]. This evidence concerns the gene CD40 and neoplasm.